Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

---

Vokes N. I., Gandara D. R., Sezer A., Kilickap S., Gumus M., Bondarenko I., ...More

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• City: Illinois
• Country: United States Of America
• Istanbul University-Cerrahpasa Affiliated: No